Axon Enterprise (NASDAQ:AXON) President Joshua Isner Sells 20,000 Shares

Axon Enterprise, Inc (NASDAQ:AXON) President Joshua Isner sold 20,000 shares of the business’s stock in a transaction on Monday, December 8th. The stock was sold at an average price of $552.60, for a total value of $11,052,000.00. Following the completion of the transaction, the president directly owned 249,502 shares in the company, valued at approximately $137,874,805.20. This represents a 7.42% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.

Joshua Isner also recently made the following trade(s):

• On Wednesday, December 3rd, Joshua Isner sold 2,041 shares of Axon Enterprise stock. The stock was sold at an average price of $535.11, for a total transaction of $1,092,159.51.

Axon Enterprise Stock Performance

NASDAQ AXON opened at $546.65 on Wednesday. The company has a market capitalization of $43.14 billion, a PE ratio of 172.99, a price-to-earnings-growth ratio of 127.04 and a beta of 1.40. The company has a debt-to-equity ratio of 0.57, a quick ratio of 2.89 and a current ratio of 3.12. Axon Enterprise, Inc has a 52-week low of $469.24 and a 52-week high of $885.91. The company has a 50-day simple moving average of $632.62 and a 200 day simple moving average of $717.52.

Axon Enterprise (NASDAQ:AXON) last released its earnings results on Wednesday, November 5th. The biotechnology company reported $1.17 earnings per share for the quarter, missing analysts’ consensus estimates of $1.63 by ($0.46). The company had revenue of $710.64 million for the quarter, compared to the consensus estimate of $704.83 million. Axon Enterprise had a net margin of 10.05% and a return on equity of 4.29%. The firm’s revenue was up 30.6% on a year-over-year basis. During the same period in the prior year, the company earned $1.45 earnings per share. On average, research analysts predict that Axon Enterprise, Inc will post 5.8 EPS for the current year.

Analyst Ratings Changes

Several equities research analysts have commented on the stock. Wall Street Zen downgraded shares of Axon Enterprise from a “hold” rating to a “sell” rating in a report on Saturday, November 8th. JMP Securities reaffirmed a “market outperform” rating and set a $825.00 target price on shares of Axon Enterprise in a report on Monday, September 29th. Needham & Company LLC reissued a “buy” rating and issued a $870.00 price target on shares of Axon Enterprise in a report on Wednesday, September 24th. Royal Bank Of Canada initiated coverage on shares of Axon Enterprise in a research note on Monday, November 17th. They set an “outperform” rating and a $860.00 price objective for the company. Finally, Barclays lowered their target price on shares of Axon Enterprise from $861.00 to $702.00 and set an “overweight” rating on the stock in a research note on Thursday, November 6th. Fourteen research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $815.00.

Institutional Trading of Axon Enterprise

Hedge funds have recently made changes to their positions in the stock. TCI Wealth Advisors Inc. bought a new position in shares of Axon Enterprise during the 2nd quarter valued at approximately $214,000. Wealthedge Investment Advisors LLC boosted its holdings in shares of Axon Enterprise by 180.7% during the 2nd quarter. Wealthedge Investment Advisors LLC now owns 1,204 shares of the biotechnology company’s stock valued at $997,000 after purchasing an additional 775 shares during the last quarter. Jaffetilchin Investment Partners LLC raised its stake in Axon Enterprise by 11.7% during the second quarter. Jaffetilchin Investment Partners LLC now owns 5,938 shares of the biotechnology company’s stock valued at $4,916,000 after purchasing an additional 624 shares in the last quarter. Vanguard Group Inc. grew its position in Axon Enterprise by 3.5% in the second quarter. Vanguard Group Inc. now owns 8,937,260 shares of the biotechnology company’s stock worth $7,399,515,000 after acquiring an additional 305,252 shares in the last quarter. Finally, Duncker Streett & Co. Inc. boosted its holdings in shares of Axon Enterprise by 3.2% in the 2nd quarter. Duncker Streett & Co. Inc. now owns 14,501 shares of the biotechnology company’s stock worth $12,006,000 after purchasing an additional 448 shares during the period. 79.08% of the stock is owned by institutional investors.

Axon Enterprise Company Profile

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.